MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer

Chen, Aihua; Qin, Yue; Tang, Wen-Fan; Tao, Jing; Song, Huamei; Zuo, Mingzhang

doi:10.1186/s12935-017-0431-9

Cited by 59 publications

(38 citation statements)

References 48 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is negatively associated with lymph node metastasis and advanced FIGO stage, having the potential of being used as a prognostic biomarker [143][144][145]. miR-34a and miR-206 could also be possible prognostic instruments as their low expression in cervical cancer was linked to late stage disease, lymph node dissemination, and low survival rates [165].…”

Section: Mirnas In Cervical Cancermentioning

confidence: 99%

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Condrat

Thompson

Barbu

et al. 2020

Cells

853

583

View full text Add to dashboard Cite

MicroRNAs (miRNAs) represent a class of small, non-coding RNAs with the main roles of regulating mRNA through its degradation and adjusting protein levels. In recent years, extraordinary progress has been made in terms of identifying the origin and exact functions of miRNA, focusing on their potential use in both the research and the clinical field. This review aims at improving the current understanding of these molecules and their applicability in the medical field. A thorough analysis of the literature consulting resources available in online databases such as NCBI, PubMed, Medline, ScienceDirect, and UpToDate was performed. There is promising evidence that in spite of the lack of standardized protocols regarding the use of miRNAs in current clinical practice, they constitute a reliable tool for future use. These molecules meet most of the required criteria for being an ideal biomarker, such as accessibility, high specificity, and sensitivity. Despite present limitations, miRNAs as biomarkers for various conditions remain an impressive research field. As current techniques evolve, we anticipate that miRNAs will become a routine approach in the development of personalized patient profiles, thus permitting more specific therapeutic interventions.Biogenesis of miRNA begins in the nucleus, where the transcription of its precursor, primary miRNA or pri-miRNA takes place under the influence of RNA polymerases II and III [11,12]. The resulting molecule is a hairpin-like structure, which contains a loop at one end [11]. This primordial mi-RNA precursor that is usually made up of hundreds of nucleotides is then processed consecutively by two RNase III enzymes [13][14][15]. The first enzyme to act upon the pri-miRNA, which still resides in the nucleus, is called Drosha or DCGR8, and turns it into a new hairpin-like structure of approximately 70 nucleotides, the Precursor-miRNA or pre-miRNA. The latter is then transported to the cytoplasm, with the help of Exportin-5, where it is cleaved again by the Ago2/Dicer complex leading to the short, mature miRNA double strands [16].Further on, one of the strands, usually known as the guide strand, will be integrated into the RNA-induced silencing complex (RISC), while the other one, known as the passenger strand, is going to be degraded, even though in some occasions it has been found to be also functional [17]. In most cases, the strand that contains the less stable 5 end or a uracil at the beginning is more likely to be selected as the guide strand [18][19][20]. In those situations, where the passenger strand is not degraded and both get incorporated into the miRISC complex, the mature miRNA in the guide strand will be the dominant one [21,22].The main role of miRNA in the human body is gene regulation [23] by mediating the degradation of mRNA and also by regulating transcription and translation through canonical and non-canonical mechanisms [4]. The canonical mechanism means that the miRISC complex containing the miRNA guide strand is exerting its action by binding to the targ...

show abstract

Section: Mirnas In Cervical Cancermentioning

confidence: 99%

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Condrat

Thompson

Barbu

et al. 2020

Cells

853

583

View full text Add to dashboard Cite

show abstract

“…MicroRNA-34a has attracted interest recently because of its ability to modulate a myriad of oncogenic functions in different cancers [21][22][23][24][25][26][27]. Not only does it play a role in cancer metastasis [28,29] and drug resistance [30], it is now being evaluated as a diagnostic as well as a prognostic biomarker [31][32][33]. In addition, a miR-34a inhibitor has been identified that may effectively protect against sevoflurane-induced hippocampal apoptosis by targeting Wnt1 and activating the Wnt/β-catenin pathway [34].…”

Section: Introductionmentioning

confidence: 99%

miR-34a regulates adipogenesis in porcine intramuscular adipocytes by targeting ACSL4

Wang

Ding

et al. 2020

BMC Genet

View full text Add to dashboard Cite

Background: Intramuscular fat (IMF) content is an important factor in porcine meat quality. Previously, we showed that miR-34a was less abundant in liver tissue from pigs with higher backfat thickness, compared to pigs with lower backfat thickness. The purpose of this present study was to explore the role of miR-34a in adipogenesis. Result: Bioinformatics analysis identified Acyl-CoA synthetase long chain family member 4 (ACSL4) as a putative target of miR-34a. Using a luciferase reporter assay, we verified that miR-34a binds the ACSL4 mRNA at the 3'UTR. To examine the role of the miR-34a-ACSL4 interaction in IMF deposition in the pig, mRNA and protein expression of the ACSL4 gene was measured in primary intramuscular preadipocytes transfected with miR-34a mimic and inhibitor. Our results showed that ACSL4 is expressed throughout the entire differentiation process in pig preadipocytes, similar to the lipogenesis-associated genes PPARγ and aP2. Transfection with miR-34a mimic reduced lipid droplet formation during adipogenesis, while miR-34a inhibitor increased lipid droplet accumulation. Transfection with miR-34a mimic also reduced the mRNA and protein expression of ACSL4 and lipogenesis genes, including PPARγ, aP2, and SREBP-1C, but increased the expression of steatolysis genes such as ATGL and Sirt1. In contrast, the miR-34a inhibitor had the opposite effect on gene expression. Further, knockdown of ACSL4 decreased lipid droplet accumulation. Conclusions: Our results support the hypothesis that miR-34a regulates intramuscular fat deposition in porcine adipocytes by targeting ACSL4.

show abstract

“…Additionally, recent studies have also shown that miR-206, a tumor suppressor miRNA that targets several oncogenes, was under expressed in many tumors [16-20], miR-206 inhibited cell proliferation, invasion and/or apoptosis by targeting SOX9 in lung cancer [16], Tbx3 in breast cancer [18], CDK9 in hepatocellular carcinoma [19], HDAC6in head and neck squamous cell carcinoma [20], ANXA2 in osteosarcoma [21], Bcl-2 in colorectal cancer [29], CXCL11 in prostate cancer [30], HDAC6 in squamous cell carcinoma [27], and cell metastasis by targeting MKL1/IL11 in breast cancer [17], FMNL2 in colorectal cancer [31], CXCL11 in prostate cancer [30]. And serum miR-206 might serve as a diagnostic biomarker in cancers, such as gastric cancer [32], renal cell carcinoma [33], also as a novel prognostic and therapeutics in cervical cancer [34]. In the study, we showed that inhibition of KIF2A by miR-206 decreased ovarian cancer cells A2780 and SKOV3 proliferation, migration and invasion and increased apoptosis.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of KIF2A is Suppressed by miR-206 and Associated with Poor Prognosis in Ovarian Cancer

Sheng¹,

Xu²,

Xi³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: This study aimed to investigate the expression and prognostic value of kinesin family member 2A (KIF2A) and the suppression effects of microRNA-206 (miR-206) on KIF2A in ovarian cancer. Methods: Ovarian cancer tissues from patients and ovarian cancer cell lines (A2780 and SKOV3) were used in this study. miR-206 mimics and control were transiently transfected into cells. RT-qPCR was performed to detect KIF2A mRNA and miR-206 expression levels, Western blot was performed to detect KIF2A protein levels, Dual-Luciferase Reporter Assay was used to examine the inhibition effects of miR-206 on KIF2A mRNA, immunohistochemical staining was used to examine the expression of KIF2A in tissue sections. CCK-8, transwell and Annexin-V-FITC/Propidium Iodide staining with flow cytometry were used to detect the cell proliferation, migration/invasion, and apoptosis respectively. Results: Our study explored the expression profiles of KIF2A and miR-206 in the patients with ovarian cancer. We found that overexpression of KIF2A was associated with a poor prognosis in ovarian cancer. We also found that KIF2A mRNA contains two target sites for miR-206 binding and confirmed that miR-206 directly suppresses KIF2A; inhibits ovarian cancer cell proliferation, migration, and invasion; and induces apoptosis. Conclusion: The results suggest KIF2A could serve a valuable prognostic indicator in ovarian cancer and provide a rationale for treatment of ovarian cancer by targeting KIF2A via miR-206.

show abstract

MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer

Cited by 59 publications

References 48 publications

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

miR-34a regulates adipogenesis in porcine intramuscular adipocytes by targeting ACSL4

Overexpression of KIF2A is Suppressed by miR-206 and Associated with Poor Prognosis in Ovarian Cancer

Contact Info

Product

Resources

About